Regeneron, Sanofi arthritis drug fails late-stage study in COVID-19 patients

Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a late-stage study testing it in COVID-19 patients.

A separate Sanofi-led trial outside of the United States in hospitalized patients with severe and critical COVID-19 using a different dosing regimen is ongoing, the companies said.

The trial results come after a study in April showed that Kevzara may only help the sickest coronavirus patients.

https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms/regeneron-sanofi-arthritis-drug-fails-late-stage-study-in-covid-19-patients-idUSKBN24337U